Frontlight ResearchEarly access
Active, not recruitingPhase 2
Efficacy and tolerability of the combination of anifrolumab (300 mg IV) and phototherapy versus phototherapy in adults with progressive vitiligo
Key facts
- Who runs it
- Centre Hospitalier Universitaire De Bordeaux
- Where
- France5 sites in 1 countryChoose a country to see its sites
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 48 people, planned
- Started
- 27 Nov 2023
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Record updated
- 13 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Subject male or female aged ≥ 18 years and ≤ 65 years
- Subject with body weight > or = 40kg
- Diagnosis of non-segmental (symmetrical) vitiligo with a body surface area involved >5% excluding hands and feet
- Active non-segmental vitiligo is defined by: • Non-segmental vitiligo with new patches or extension of old lesions during the last 6 months AND • Presence of hypochromic aspect under Wood’s lamp examination and/or perifollicular hypopigmentation under Wood’s lamp examination
- Able to read, understand, and give documented (electronic or paper signature) informed consent
- Affiliated or beneficiary of the French Social Security
- Agree to discontinue the use of the following excluded medications/treatments for at least 4 weeks prior to randomization (Visit 2): phototherapy
- Agree to discontinue the use of the following excluded medications/treatments for at least 4 weeks prior to randomization and throughout the study: systemic steroids, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine
- Agree to discontinue the use of the following excluded medications for at least 2 weeks prior to randomization and throughout the study: • TCS or topical immune modulators (e.g., tacrolimus or pimecrolimus) • Topical phosphodiesterase type 4 (PDE-4) inhibitor (crisaborole) • Topical JAK inhibitor (e.g., tofacitinib or ruxolitinib) and/or any other investigational topical treatments
Who cannot take part
- Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus) that would interfere with evaluations of the effect of study medication on vitiligo
- Patients who are currently experiencing a skin infection that requires treatment, or who are currently being treated, with topical or systemic antibiotics. Note: Patients may not be rescreened until at least 4 weeks after the date of their previous screen failure and at least 2 weeks after resolution of the infection
- Have any serious concomitant illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma)
- Current alcohol, drug, or chemical abuse
- Patients with history of basal cell or squamous epithelial skin cancer or melanoma
- Presence of significant uncontrolled neuropsychiatric disorder, are clinically judged by the investigator to be at risk for suicide
- Segmental or mixed vitiligo
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy of the combination of anifrolumab intravenous (IV) every four weeks + UVB TL01 (twice a week) by the evaluation of the percentage of skin repigmentation after 36 weeks of treatment using the VASI score in the experimental group receiving anifrolumab + UVB TL01.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Efficacy and tolerance of the association of ANIFROLUMAB (300mg) IV every four weeks and phototherapy versus phototherapy in adults with progressive vitiligo: a randomized double blind prospective, non comparative Proof of Concept phase II study - VITANI
- Record updated
- 13 January 2026